C. Fotiadou, E. Lazaridou and D. Loannides, “Safety of Anti-Tumour Necrosis Factor-α Agents in Psoriasis Patients Who Were Chronic Hepatitis B Carriers: A Retrospective Report of Seven Patients and Brief Review of the Literature,” Journal of the European Academy of Dermatology and Venereology, Vol. 25, No. 4, 2011, pp. 471-474. doi:10.1111/j.1468-3083.2010.03754.x

has been cited by the following article:

• TITLE: Reactivation of Hepatitis B after Administration of Anti-TNFα in a Patient with Psoriasis

  AUTHORS: Tania Díaz Corpas, Almudena Mateu Puchades, Ana Zayas Gavilá, Amparo Marquina Vila

  KEYWORDS: Hepatitis B Virus Infection; Anti-TNFα Agent; Psoriasis, Viral Reactivation; Adalimumab

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.3 No.2, March 16, 2012

  ABSTRACT: In patients with severe psoriasis that at the same time have multiple comorbidities and chronic infections, is difficult to establish safer and more effective therapy. There are contradictions between the indications of the international protocols of systemic treatments, and the most recent publications which show that anti-TNFα agents could be safe therapeutic options in patients with chronic hepatitis. In the case of chronic viral infections, specifically hepatitis B, there are several conflicts in reference to the biological treatments that can block tumoral necrosis factor-α (TNFα) because there is evidence of a risk of reactivation of hepatitis. Most viral reactivations with the administration of an anti-TNFα agent have been reported in patients with inflammatory diseases. However, there are a few cases described in psoriasis. We’ll present the first case reported in literature of hepatisis B viral (HBV) reactivation in a patient with severe psoriasis secondary to the administration of adalimumab.